

Sub B¹
A³
6) (Amended) The process of claim 5 wherein the nucleic acid is selected from the group consisting of DNA, RNA, plasmid DNA, and nucleic acid contained in viruses.

7) (Amended) The process of claim 1 wherein the nucleic acid modifies expression in a cell [of cellular material].

8) (Amended) The process of claim 7 wherein introducing [inserting] the nucleic acid comprises injecting the nucleic acid.

10) (Amended) The process of claim 9 wherein delivering the nucleic acid includes increasing the blood vessel permeability.

11) (Amended) The process of claim 10 wherein the nucleic acid is selected from the group consisting of DNA, RNA, plasmid DNA, oligonucleotides, and nucleic acid contained in viruses.

12) (Amended) The process of claim 4 wherein [delivering] injecting the nucleic acid includes [changing] injecting a predetermined volume of nucleic acid during a predetermined time.

Sub B⁵
A⁴
13) (Amended) The process of claim 12 wherein delivering the nucleic acid includes increasing the blood vessel permeability.

14) (Amended) The process of claim 13 wherein the nucleic acid is selected from the group consisting of DNA, RNA, plasmid DNA, and nucleic acid contained in viruses.

Sub B⁶
15) (Amended) The process of claim 4 [9] wherein delivering the nucleic acid includes increasing internal pressure of the blood vessel.

16) (Amended) The process of claim 15 wherein delivering the nucleic acid includes increasing the blood vessel permeability.

17) (Amended) The process of claim 16 wherein the nucleic acid is selected from the group consisting of DNA, RNA, plasmid DNA, and nucleic acid contained in viruses.

Sub B⁷
18) (Amended) A process for gene therapy, comprising:

- a) inserting a nucleic acid into a blood vessel having a channel leading to heart muscle [cardiac tissue];
- b) delivering the nucleic acid to a heart muscle [cardiac tissue] cell; and,
- c) expressing the nucleic acid to provide a therapeutic protein.

REMARKS

Objection to the Specification under 35 U.S.C. 112: